Venture Tracks

Venture tracks

Kevin Johnson joined Index Ventures as a partner. He will seek new biologics assets employing Index's "asset-centric" model (see BioCentury, Dec. 7, 2009). Johnson has been a venture advisor to Index and was CEO of PanGenetics B.V., which is an Index portfolio company. PanGenetics sold a Phase I antibody against nerve growth factor to Abbott Laboratories (NYSE:ABT) for $170 million up front and the potential for another $20 million in milestones (see BioCentury, Nov. 16)...